Testosterone and the heart

International Journal of Clinical Practice

Volumn 66, Issue 7, 2012, Pages 648-655

  Hackett, G ^a  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SEX HORMONE; TESTOSTERONE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ANDROGEN THERAPY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DRUG EFFICACY; EXERCISE; HUMAN; MORTALITY; MUSCLE FUNCTION; MUSCLE STRENGTH; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACOLOGICAL BLOCKING; PREDICTION; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; STROKE; SYSTOLIC BLOOD PRESSURE; TESTOSTERONE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; HORMONE REPLACEMENT THERAPY; HUMANS; MALE; RISK FACTORS; SURVIVAL ANALYSIS; TESTOSTERONE;

EID: 84862743994     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2012.02922.x     Document Type: Review

References (49)

1. Wang C, Nieschlag E, Swerdloff RS, et al., Investigation, treatment, and monitoring of late-onset hypogonadism in Males;ISA, ISSAM,EAU,EAA,ASA Recommendation. Eur Urol 2009; 55: 21-130.
2. Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, O'Neill T,. Identification of Late-Onset Hypogonadism in Middle-Aged and Elderly Men (EMAS). N Engl J Med 2010; 363: 123-35.
3. Stellato RK, Feldman HA, Hamdy O, Horton ES, McKinlay JB,. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diabet Care 2000; 23: 490-4. (Pubitemid 30185792)
4. Khaw KT, Dowsett M, Folkerd E, et al., Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) prospective population study. Circulation 2007; 116: 2694-701. (Pubitemid 350291241)
5. Oh JY, Barrett-Connor E, Wedick NM, Wingard DL,. Endogenous sex hormones and the development of type 2 diabetes in older men and women; the Rancho Bernardo study. Diabet Care 2002; 25: 55-60. (Pubitemid 41070783)
6. Shores MM, Matsumoto AM, Sloan KL, et al., Low serum testosterone and mortality in male veterans. Arch Intern Med 2006; 166: 1660-5. (Pubitemid 44232378)
7. Hak AE, Witteman JCM, De Jong FH, et al., Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam Study. J Clin Endocrinol Metab, 2002; 87: 3632-9. (Pubitemid 34879505)
8. Tivesten A, Vandenput L, Labrie F, Karlsson M, et al., Low serum testosterone and estradiol predict mortality in elderly men. J Endocrinol and Metab 2009; 94: 2482-8.
9. Vikan T, Schirmer H, Njølstad I, Svartberg J,. Endogenous sex hormones and the prospective association with cardiovascular disease and mortality in men: the Tromsø Study. Eur J Endocrinol 2009; 161: 435-42.
10. Corona G, Monami M, Boddi V, Cameron-Smith, et al., Low testosterone is associated with increased risk of MACE lethality in subjects with erectile dysfunction. J Sex Med 2010; 7: 1557-64.
11. Maggio M, Laurentini F, Ceda GP, et al., Relationship between low levels of anabolic hormones and 6 year mortality in older men in the Chianti area. Arch Int Med 2007; 167: 2249-54. (Pubitemid 350106746)
12. Hyde Z, Norman P, Flicker L, Hankey G, Almeida P, et al., Low free testosterone predicts mortality from cardiovascular disease but not other causes: the Health in Men Study. J Clin Endocrin Metab 2012; 1: 179-89.
13. Yeap B, Hyde Z, Almeida OP, et al., Low testosterone levels predict incident stroke and transient ichaemic attack in older men. J Clin Endocrinol Metab 2009; 94: 2353-9.
14. Araujo AB, Dixon JM, Suarez EA, Murad MH, Guey LT, Wittert GA,. Endogenous testosterone and mortality in men: a systemic review and meta-analysis. J Clin Endocrinol Metab 2011; 96: 3007-19.
15. Haring R, Volzke H, Steveling A, et al., Association of low testosterone levels with all-cause mortality by different cut-offs from recent studies. Eur Heary J 2010; 31: 1494-501.
16. Bassin S, Cunningham GR, Hayes FJ, Matsumoto AM, et al., Testosterone therapy in adult men with androgen deficiency syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2006; 91: 1995-2010. (Pubitemid 43854972)
17. Malkin cJ, Pugh PJ, Morris PD, et al., Serum testosterone and increased mortality in men with coronary heart disease. Heart 2010; 96: 1821-5.
18. Muraleedaran V, Jones CH,. Endocrine Abstracts 2010; 21: P174.
19. Kapoor D, Aldred H, Clark S, et al., Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes, Correlations with bioavailable testosterone and visceral adiposity. Diabet Care 2007; 30: 911-7. (Pubitemid 46556586)
20. Hackett G, Cole N, Deshpande A, et al., Biochemical hypogonadism in men with type 2 diabetes. Primary Care Pract 2009; 9: 226-31.
21. Malkin CJ, Pugh PJ, Jones RD, Kapoor D, Channer KS, Jones TH,. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Cli Endocrinol Metab 2004; 89: 3313-8. (doi:) (Pubitemid 38951897)
22. Kalinchenko S, Tishova Y, Mskhalaya G, Gooren L, Giltay E, Saad F,. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Cli Endocrinol 2010; 73: 602-12.
23. Zgliczynski S, Ossowski M, Slowinska-Srzednicka J, et al., Effect of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elderly men. Atherosclerosis 1996; 121: 35-43. (doi:)
24. Jones T,. A placebo controlled study on the effects of transdermal testosterone gel in hypogonadal men with type II diabetes or metabolic syndrome in diabetic control and insulin sensitivity: the TIMES 2 study. Diabet Care 2011; 34: 828-37.
25. Hackett G, Cole N,. Long acting testosterone undecanoate improves diabetes control v placebo in a hypogonadal population with type 2 diabetes PO-05-12. J sex Med 2011; 8: 430.
26. Haffner SM, Shaten J, Stern MP, Smith GD, Kuller L,. Low levels of sex hormone-binding globulin and testosterone predict the development of non-insulin-dependent diabetes mellitus in men. MRFIT Research Group. Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996; 143: 889-97. (Pubitemid 26131096)
27. Heufelder AE, Saad F, Bunck MC, Gooren L,. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl 2009; 30: 726-33. (doi:10. 2164/jandrol.108.007005)
28. Maggio M, Basaria S, Ble A, et al., Correlation between testosterone and the inflammatory marker soluble interleukin-6 receptor in older men. J Cli Endocrinol Metab 2006; 91: 345-7. (doi:). (Pubitemid 43069161)
29. Guler N, Batyraliev T, Dulger H, et al., The effects of short term (3 weeks) testosterone treatment on serum inflammatory markers in men undergoing coronary artery stenting. Int J Cardiol 2006; 109: 339-43. (doi:. 06.027) (Pubitemid 44275132)
30. Kapoor D, Goodwin E, Channer KS, Jones TH, et al., Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolemia in hypogonadal men with Type 2 diabetes. Eur J Endocrinol 2006; 154: 899-906. (Pubitemid 43997730)
31. Naharci MI, Pinar M, Bolu E, Olgun A,. Effect of testosterone on insulin sensitivity in men with idiopathic hypogonadotropic hypogonadism. Endocr Pract 2007; 13: 629-35.
32. Boyanov MA, Boneva Z, Christov VG,. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male 2003; 6: 1-7. (Pubitemid 36606394)
33. Giltay EJ, Tishova YA, Mskhalaya GJ, et al., Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. J Sex Med 2010; 7: 2572-82.
34. The Endocrine Society. Clinical bulletins in andropause: benefits and risks of treating hypogonadism in the ageing male. Endocr Rep 2002; 2: 1-6
35. Malkin CJ, Pugh PJ, Morris PD, et al., Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart 2004; 90: 871-6. (doi:) (Pubitemid 39005930)
36. Marin P, Holmang S, Gustafsson C, et al., Androgen treatment of abdominally obese men. Obesity Res 1993; 1: 245-51.
37. Yaron M, Greenman Y, Rosenfeld JB, et al., Effect of testosterone replacement therapy on arterial stiffness in older hypogonadal men. Eur J Endocrinol 2009; 160: 839-46. (doi:)
38. Mathur A, Malkin C, Saleem B, Muthusammy R, Jones CH, Channer K,. The long term benefits of testosterone on angina threshold and atheroma in men. Eur J Endocrinol 2009; 161: 443-9.
39. Muraleedharan V, Jones CHl,. British Endocrine Society. Endocrine Abstracts 2011; 35: P163.
40. Shores M, Smith NL, Forsberg CW, Anawalt BD, Matsumoto AMl,. American Endocrine Society. Endocrine Rev 2011; 32-03: P1-772.
41. English KM, Mandour O, Steeds RP, Diver MJ, Jones TH, Channer KS,. Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. Eur Heart J 2000; 21: 890-4. (Pubitemid 30307417)
42. Malkin CJ, Pugh PJ, Jones TH, Channer KS,. Testosterone for secondary prevention in men with ischaemic heart disease? Q J Med 2003; 96: 521-9. (Pubitemid 36850168)
43. Pugh PJ, Morris PD, Hall J, et al., High prevalence of low testosterone levels in men with coronary heart disease and an association with hypertension and obesity-The South Yorkshire study. Endocrine Abs 2003; 5: 225-33.
44. English KM, Steeds RP, Jones TH, Diver MJ, Channer KS,. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study. Circulation 2000; 102: 1906-11.
45. Caminiti G, Volterrani M, Iellamo F, et al., Effect of long- acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double- blind, placebo-controlled, randomized study. J Am Coll Cardiol 2009; 54: 919-27.
46. Basaria S, Coviello A, Travison T, et al., Adverse events associated with testosterone administration. New Eng J Med 2010; 363: 109-22.
47. Calof OM, Singh AB, Lee ML, et al., Adverse events accociated with testosterone replacement in middle-aged and older men:a meta-analysis of randomised, placebo controlled trials l. J Gerontology 2005; 60A: 4051-7.
48. Haider A, Gooren LJ, Padungtod P, Saad F,. Concurrent improvement of the metabolic syndrome and lower urinary tract symptoms upon normalisation of plasma testosterone levels in hypogonadal elderly men. Andrologia 2009; 41: 7-13.
49. Saad F, Aversa A, Isidori A, et al., Onset of effects of testosterone replacement and time span until maximal effect is achieved. Eur J Endocrinol 2011; 165: 675-85.